IFRX: INF904 targets ANCA vasculitis with improved safety and efficacy, filling a key market void
A strategic pivot to ANCA vasculitis leverages a validated C5aR1 target and addresses a market gap left by competitor withdrawals. INF904 offers improved pharmacokinetics and safety, with clinical trials set to begin early next year and regulatory engagement ongoing.Based on InflaRx N.V. [IFRX] 12t…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.